DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Latest Information Update: 19 Mar 2025
At a glance
- Drugs Datopotamab deruxtecan (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms DATO-BASE
Most Recent Events
- 11 Mar 2024 Status changed from not yet recruiting to recruiting.
- 21 Dec 2023 New trial record